Kineta Inc.
Kineta Inc.
Kineta Inc.
Close
  • about
    • company
    • team
    • board
    • SAB
  • pipeline
    • overview
    • KVA12123 (VISTA)
    • CD27
  • partnerships
  • investors
    • overview
    • press releases
    • events & presentations
    • stock information
    • analyst coverage
    • SEC filings
    • corporate governance
    • IRS Form 8937
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean
  • about
    • company
    • team
    • board
    • SAB
  • pipeline
    • overview
    • KVA12123 (VISTA)
    • CD27
  • partnerships
  • investors
    • overview
    • press releases
    • events & presentations
    • stock information
    • analyst coverage
    • SEC filings
    • corporate governance
    • IRS Form 8937
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean

[be_recent_posts_author_no_link title=”Latest News from Kineta” category_id=”4,3″ num_posts=”6″ post_offset=”0″ num_words_limit=”0″ show_date_author=”1″ show_more_link=”0″ more_link_text=”Read more” show_thumbs=”0″ remove_thumb_frame=”0″ thumb_frame_shadow=”0″ default_thumb=”0″ post_thumb_width=”100″ post_thumb_height=”80″]

Recent Kineta News

  • Kineta Announces Participation at October Investor Conferences
  • Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
  • Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression
  • Kineta to Participate in Upcoming Investor Conferences
  • Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
October 17, 2022 in Biotech Industry News

BioSpace: Kineta, Merck Strike Deal to Pair Anti-VISTA Antibody with Keytruda®

Kineta Inc 8 Like Post Comments Off on BioSpace: Kineta, Merck Strike Deal to Pair Anti-VISTA Antibody with Keytruda®
Read More
Post placeholder image
August 29, 2022 in Biotech Industry News

Kineta announces the filing of a registration statement on Form S-4 with the U.S. SEC related to the reverse merger with Yumanity Therapeutics (YMTX)

Kineta Inc 9 Like Post Comments Off on Kineta announces the filing of a registration statement on Form S-4 with the U.S. SEC related to the reverse merger with Yumanity Therapeutics (YMTX)
Read More
Post placeholder image
June 7, 2022 in Biotech Industry News

Puget Sound Business Journal: Seattle biotech Kineta to go public in reverse merger deal with Yumanity Therapeutics

Kineta Inc 7 Like Post Comments Off on Puget Sound Business Journal: Seattle biotech Kineta to go public in reverse merger deal with Yumanity Therapeutics
Read More
Post placeholder image
June 6, 2022 in Biotech Industry News

GeekWire: Seattle biotech Kineta will go public in deal with neurosciences company Yumanity Therapeutics

Kineta Inc 6 Like Post Comments Off on GeekWire: Seattle biotech Kineta will go public in deal with neurosciences company Yumanity Therapeutics
Read More
Post placeholder image
May 26, 2022 in Biotech Industry News

Life Sciences Review Selects Kineta as Top Biotech Startup of 2022

Kineta Inc 7 Like Post Comments Off on Life Sciences Review Selects Kineta as Top Biotech Startup of 2022
Read More
Post placeholder image
September 23, 2020 in Biotech Industry News

Kineta Listed in Nature BioPharma Dealmakers of 2020

Kineta Inc 8 Like Post Comments Off on Kineta Listed in Nature BioPharma Dealmakers of 2020
Read More
Post placeholder image
September 15, 2020 in Biotech Industry News

Pharma Tech Outlook Top 10 Immunotherapy Companies 2020

Kineta Inc 6 Like Post Comments Off on Pharma Tech Outlook Top 10 Immunotherapy Companies 2020
Read More
Post placeholder image
August 31, 2020 in Biotech Industry News

Kineta Named Immunotherapy Company of the Year by Pharma Tech Outlook

Kineta Inc 8 Like Post Comments Off on Kineta Named Immunotherapy Company of the Year by Pharma Tech Outlook
Read More
Post placeholder image
May 20, 2020 in Biotech Industry News

Shawn Iadonato Named as One of the Top 50 Healthcare Technology CEOs of 2020

Kineta Inc 8 Like Post Comments Off on Shawn Iadonato Named as One of the Top 50 Healthcare Technology CEOs of 2020
Read More
Post placeholder image
May 13, 2020 in Biotech Industry News

Seattle Biotech CEO Keeps A Watchful Eye on the Market for Potential IPO

Kineta Inc 8 Like Post Comments Off on Seattle Biotech CEO Keeps A Watchful Eye on the Market for Potential IPO
Read More
Prev123…6Next

219 Terry Ave. N. Suite 300. Seattle, WA 98109

Sign Up for Email Alerts

219 Terry Ave. N. Suite 300. Seattle, WA 98109

  • about
  • pipeline
  • partnerships
  • investors
  • contact
Sign Up for Email Alerts

© 2023 Kineta Inc.        Privacy Policy       Terms of Use

English
English
Korean